Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
I-Mab Catalyst Calendar
Proactively evaluate I-Mab’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of I-Mab Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
24 Nov 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
30 Sep 2020 | Phase I/II Trial Results | AbbVie Inc; I-Mab; Merck & Co Inc; Tianjing Biotechnology (Shanghai) Co Ltd | ABBV; IMAB; MRK | lemzoparlimab | Oncology | B-Cell Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Follicular Lymphoma; Lymphoma; Marginal Zone B-cell Lymphoma; Non-Hodgkin Lymphoma; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Peritoneal Cancer; Primary Mediastinal B-Cell Lymphoma; Solid Tumor; Transitional Cell Cancer (Urothelial Cell Cancer) | Company Press Release |
01 Jul 2020 | Phase I Trial Initiation | I-Mab | IMAB | plonmarlimab | Immunology | Rheumatoid Arthritis | Clinical Trial Registry |
15 Apr 2020 | Phase I/II Trial Initiation | I-Mab; Tianjing Biotechnology (Shanghai) Co Ltd | IMAB | lemzoparlimab | Oncology | Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer